Skip to main content
Premium Trial:

Request an Annual Quote

Ochsner Health Integrating ActX Genomic Decision Support to Pilot Cancer PGx Project

NEW YORK – New Orleans-based Ochsner Health on Wednesday said it is piloting a pharmacogenomics project, in which it will integrate ActX Genomic Decision Support within its Epic electronic health records to alert doctors to how cancer patients are likely to respond to various drugs based on their genomic profile.

The ActX platform will allow physicians to check drug-gene interactions in real time in the EHR workflow against the therapies cancer patients are prescribed, provide a genomic profile in each patient's chart, and enable assessment of actionable hereditary risks. The decision support system will alert doctors if, based on patients' genomic profiles, they are likely to have a limited response to a drug or experience adverse reactions, or if they need a different drug dose.

"The ability to predict ahead of time which drugs will be effective for a unique patient across many different clinical scenarios and to identify in real time which medications may cause patients serious issues, will save lives and improve the quality of our care while also being more cost effective," Marc Matrana, director of Ochsner Precision Cancer Therapies Program, said in a statement.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.